In addition, HER2 2+/ISH-negative breast cancer had a marginal but significant survival advantage compared to HER2 1+ breast cancer (HER2 2+/ISH negative vs. HER2 1+, HR 0.95, 95% CI (0.93–0.98), p < 0.001). The gene discussed is ERBB2; the disease is breast carcinoma.